AMLX
Amylyx Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$1.88B
P/E Ratio
—
EPS
$-1.53
Beta
-0.21
52W High
$18.61
52W Low
$4.20
50-Day MA
$15.13
200-Day MA
$12.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.77
PEG Ratio
—
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating innovative therapies for neurodegenerative conditions, with a strong emphasis on amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, showcases a novel neuroprotective mechanism that aims to significantly improve patient outcomes, representing a promising advancement in ALS treatment. With a solid clinical development pipeline and a deep expertise in the nuances of neurological disorders, Amylyx is strategically positioned to address urgent unmet medical needs in ALS and potentially other related diseases, making it a compelling prospect for institutional investors.
Fundamentals
| Revenue (TTM) | -665,000 |
| Gross Profit (TTM) | $-90.40M |
| EBITDA | $-152.77M |
| Operating Margin | 0.00% |
| Return on Equity | -61.60% |
| Return on Assets | -36.40% |
| Revenue/Share (TTM) | $-0.01 |
| Book Value | $2.78 |
| Price-to-Book | 6.14 |
| Price-to-Sales (TTM) | 0.66 |
| EV/Revenue | 6446.63 |
| EV/EBITDA | -11.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $111.09M |
| Float | $82.88M |
| % Insiders | 7.92% |
| % Institutions | 104.07% |
Historical Volatility
HV 10-Day
41.21%
HV 20-Day
55.58%
HV 30-Day
53.33%
HV 60-Day
57.93%
HV Rank
6.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($22.80 target)
11
Buy1
HoldData last updated: 4/29/2026